SCHEDULE: Beryl Capital Exits Inozyme Pharma Stake
Beneficial Ownership Amendment
Beryl Capital Management and related entities report 0% beneficial ownership in Inozyme Pharma, Inc., signaling a complete divestment.
Summary
- Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin have filed an Amendment No. 1 to Schedule 13G.
- The filing reports that these entities and individuals beneficially own 0.00 shares of Inozyme Pharma, Inc. Common Stock, representing 0% of the class.
- This update indicates a complete divestment of their previously held stake in Inozyme Pharma, Inc., as of the event date.
- The securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as it is a factual disclosure of a change in ownership, not reflecting on the issuer's performance or prospects.
Risks
- No new risks for Inozyme Pharma, Inc. are disclosed in this ownership update.
Industry Context
This filing is a routine disclosure of a change in institutional ownership, specifically a divestment. It does not provide insights into broader industry trends or competitive landscape for Inozyme Pharma, Inc.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Joint Filing Agreement | An agreement was established for the joint filing of Schedule 13D or 13G and Forms 3, 4, or 5 by Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin. | 08/05/2025 | Streamlines future SEC reporting for the involved parties regarding their holdings. |
Stakeholder Impact
- Shareholders: Indicates a significant institutional investor has fully divested its stake, which could be interpreted differently by the market depending on prior expectations.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement, indicating the point at which beneficial ownership dropped to 0%. |
| 07/31/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
| 08/05/2025 | Date of the Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. |
Keywords
Inozyme Pharma, Beryl Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Divestment, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.